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Background: Spenic hemangiosarcoma (HSA) in dogs treated with surgery alone is associated with short survival
times, and the addition of doxorubicin (DOX) chemotherapy only modestly improves outcome. The purpose of this
study was to evaluate the impact of toceranib administration on progression free survival in dogs with stage I or II
HSA following splenectomy and single agent DOX chemotherapy. We hypothesized that dogs with splenic HSA
treated with adjuvant DOX followed by toceranib would have prolonged disease-free interval (DFI) and overall
survival time (OS) when compared to historical dogs treated with DOX-based chemotherapy alone.
Results: Dogs with stage I or II splenic HSA were administered 5 cycles of single-agent DOX every 2 weeks
beginning within 14 days of splenectomy. Dogs were restaged 2 weeks after completing DOX, and those without
evidence of metastatic disease began toceranib therapy at 3.25 mg/kg every other day. Forty-three dogs were
enrolled in this clinical trial. Seven dogs had evidence of metastatic disease either before or at re-staging, and an
additional 3 dogs were found to have metastatic disease within 1 week of toceranib administration. Therefore 31
dogs went on to receive toceranib following completion of doxorubicin treatment. Twenty-five dogs that received
toceranib developed metastatic disease. The median disease free interval for all dogs enrolled in this study (n = 43)
was 138 days, and the median disease free interval for those dogs that went on to receive toceranib (n = 31) was
161 days. The median survival time for all dogs enrolled in this study was 169 days, and the median survival time
for those dogs that went on to receive toceranib was 172 days.
Conclusions: The use of toceranib following DOX chemotherapy does not improve either disease free interval or
overall survival in dogs with stage I or II HSA.
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Hemangiosarcoma (HSA) is one of the more common
malignancies that arise in dogs, accounting for approxi-
mately 20 % of soft-tissue sarcomas and 5 % of all non-
cutaneous tumors [1, 2]. HSA can occur in several different
organs including the spleen, liver, heart, muscle, retroperi-
toneal space and subcutaneous tissues. In some cases, mul-
tiple primary tumors may be evident at presentation. In* Correspondence: london.20@osu.edu
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creativecommons.org/publicdomain/zero/1.0nearly all cases, metastatic disease is present at the time
of diagnosis, either in the form of microscopic or
macroscopic lesions. Consequently, the majority of dogs
diagnosed with hemangiosarcoma die within 1 year of
diagnosis, with a large proportion of dogs not surviving
beyond 6–8 months [2]. With respect to HSA involving
the spleen, surgery alone has been associated with ex-
tremely short survival times ranging from 1 to 3 months
[3–5]. The addition of doxorubicin (DOX)-based chemo-
therapy protocols (DOX alone, DOX/cyclophosphamide
and vincristine/DOX/cyclophosphamide) following surgeryarticle distributed under the terms of the Creative Commons Attribution
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(5–6 months on average), however the 1 year survival rate
is 10 % at best [6–11].
Several clinical trials have been pursued in an effort to
improve outcome in dogs with HSA, and most of these
have focused on the splenic form as resection down to
microscopic disease can be readily accomplished in many
cases. The first of these involved the use of liposome en-
capsulated muramyl tripeptide phosphatidylethanolamine
(L-MTP-PE), an immunomodulator that increases mono-
cyte tumoricidal activity [12]. This was administered to
dogs with DOX/cyclophosphamide chemotherapy follow-
ing surgery, and a significant increase in disease free sur-
vival and overall survival time were noted compared to
dogs receiving DOX/cyclophosphamide with placebo lipo-
somes, although this was restricted to dogs that presented
with Stage I disease (non-ruptured spleen). Unfortunately,
dogs with Stage II disease (ruptured spleen) did not
appear to derive significant benefit.
Another clinical trial involved the administration of a
novel HSA vaccine prepared with lysates of allogeneic
canine HSA cell lines mixed with an adjuvant composed
of liposome-DNA complexes to dogs with splenic HSA
following surgery [13]. Although vaccinated dogs mounted
strong humoral immune responses against a control anti-
gen and most dogs also mounted antibody responses
against canine HSA cells, this did not translate into an im-
provement in survival time for treated dogs. The use of a
metronomic treatment protocol consisting of piroxicam,
low dose cyclophosphamide and low dose etoposide was
evaluated in dogs with splenic HSA [14]. The therapeutic
regimen did seem to have equivalent efficacy compared
to DOX based studies, with no significant overall sur-
vival advantage noted as the median survival time was
still approximately 6 months. More recently, intracavi-
tary pegylated liposome encapsulated DOX was used to
treat dogs following splenectomy and compared con-
temporaneously to single agent DOX; again, no advan-
tage of the liposomal formulation was noted [15].
Given the failure of standard chemotherapeutic ap-
proaches and immunotherapy to significantly alter out-
comes, the potential for the use of more targeted therapies
for HSA has been investigated using both in vitro ap-
proaches and mouse models of disease. Canine HSA cell
lines and tumor samples have been shown to express the
receptor tyrosine kinases stem cell factor receptor (KIT),
platelet derived growth factor receptor (PDGFR) and vas-
cular endothelial growth factor receptor (VEGFR) family
members [16–23]. Other cell signaling elements found to
be expressed and activated include focal adhesion kinase
(FAK), SRC, and several members of the mTOR pathway
[24–26]. The small molecule masitinib which blocks func-
tion of KIT and PDGFR inhibited the proliferation and in-
duce apoptosis in canine HSA cell lines in vitro, althoughdrug concentrations necessary for this effect ranged from
8.5–10.6 uM [19]. This is higher than the Cmax achievable
in healthy beagle dogs (1.3–1.5 uM) [27]. More recently,
both imatinib and the multitargeted small molecule inhibi-
tor dasatinib (blocks KIT, PDGFR and SRC) demonstrated
activity against HSA cell lines in vitro, and imatinib signifi-
cantly reduced growth of canine HSA xenografts in mice
[16]. Together, these data support the notion that inhibi-
tors of the KIT, PDGFR, and/or VEGFR family members
may exhibit biologic activity in dogs with HSA.
Toceranib phosphate (Palladia®, Zoetis Inc) is a multitar-
geted small molecule inhibitor that blocks signaling of
KIT, PDGFR and VEGFR family members [28]. Toceranib
has demonstrated activity against multiple tumor types in-
cluding mast cell tumor, nasal carcinoma, apocrine gland
anal sac adenocarcinoma and osteosarcoma, among others
[28–30]. The purpose of this prospective clinical trial was
to evaluate the impact of toceranib administration on
progression free survival in dogs with stage I or II HSA
following splenectomy and single agent DOX treatment.
Methods
Eligibility
This clinical trial was approved by the Clinical Research
and Advising Committee at the College of Veterinary
Medicine and Institutional Animal Care and Use Com-
mittee (IAUCUC) at Ohio State University; IACUC or
similar approval was also obtained at all other participat-
ing academic and private practice veterinary centers.
Dogs with histologically confirmed stage I or II splenic
HSA that had undergone splenectomy were considered
eligible for this clinical trial. Surgical biopsy of the liver,
lymph nodes and mesentery were not required unless
there was clinical suspicion of metastatic disease at the
time of surgery. Prior to enrollment dogs underwent a
series of tests including complete blood count (CBC),
biochemistry profile, urinalysis, abdominal ultrasound,
and thoracic radiographs. Dogs with no obvious evidence
of metastatic disease on diagnostic imaging were eligible
for enrollment. Additional eligibility criteria included age
of at least 1 year, ECOG performance score of 0–1, ad-
equate organ function as indicated by routine bloodwork
(e.g., liver transaminases ≤ 3x the upper limit of normal
(ULN), creatinine ≤ 1.5x ULN), and no evidence of any
serious systemic disorder (e.g., cardiac disease) considered
incompatible with the study. Dogs were required to enroll
and begin chemotherapy within 14 days of splenectomy.
Drug product and concomitant medication
Toceranib phosphate was provided by Zoetis (Madison,
NJ) in 10, 15, and 50 mg size tablets. Concomitant
medications considered acceptable for use to prevent
and/or treat drug related toxicities included famotidine,
omeprazole, metronidazole, loperamide, metoclopramide,
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and prednisone.
Study design
A total of 43 dogs were enrolled in this study. All dogs
were treated with 5 cycles of single-agent DOX (30 mg/
m2 IV) every 2 weeks beginning within 14 days of splen-
ectomy. All dogs were re-staged with abdominal ultra-
sound and 3-view thoracic radiographs 2 weeks after
completing the final DOX treatment, and those dogs
considered free of metastatic disease received toceranib
at 3.25 mg/kg every other day (EOD). Dogs were evalu-
ated at weeks 1, 2 and 4 following initiation of toceranib
therapy and then every 4 weeks thereafter. A CBC was
performed at every visit; serum biochemistry profile and
urinalysis were performed every 8 weeks. Re-staging
consisted of 3-view thoracic radiographs and abdominal
ultrasound every 8 weeks. Dogs were evaluated for ad-
verse events (AEs) at every study visit. AEs were defined
and graded according to the published VCOG-CTCAE
criteria [31].
Assessment of progression free survival
Dogs were evaluated every 8 weeks following initiation
of toceranib therapy for evidence of metastatic disease
using both clinical evidence of disease (anemia, obvious
hemorrhage, seizures) and diagnostic imaging (thoracic
radiographs and abdominal ultrasound). If lesions were
identified via imaging that were consistent with possible
metastatic disease but could not be confirmed through
cytologic analysis, these were followed closely. If the
lesions were subsequently deemed to be true metastatic
disease based on progression as assessed by repeat
imaging, cytologic confirmation, or clinical signs (e.g.,
hemoabdomen, seizures consistent with brain metasta-
sis), the date that the lesions were first noted was con-
sidered the true date of progression, consistent with
current RECIST recommendations. This also applied to
dogs in which clinical signs were present that were
consistent with metastatic disease (e.g., seizures) which
were later confirmed with either additional imaging or
progression of signs. Recheck exams continued for a
total of 12 months from the time of surgical removal of
the spleen, after which time the study ended and follow-
up recommendations were provided at the discretion of
the attending clinician.
Statistical analysis
Thirty-eight dogs were to enter this multi-center, single-
arm trial over 18 months, with an additional 6 months
for follow-up. It was anticipated that 6–8 of these dogs
would fail chemotherapy and not be eligible to continue
on to toceranib treatment, with a minimum of 30 dogs
continuing on to receive toceranib therapy followingrestaging. A historical control group was used for the
power analysis in the current study. This control group
consisted of 21 dogs treated with stage I or II splenic
HSA treated with splenectomy and single agent DOX
every 2 weeks (unpublished data). One of the co-authors
of this study (D. Thamm) provided the raw data from
the dogs for the power analysis. Assuming a significance
of 0.05 this study was powered to detect a 2-fold in-
crease in median disease free interval or hazard ratio
with 80 % power if 30 dogs went on to receive toceranib
treatment following completion of DOX chemotherapy.
A total of 38 dogs were planned for enrollment assuming
attrition due to metastatic disease identified either during
or immediately following completion of DOX treatment.
An additional 5 dogs were added to the initial 38 antici-
pated for a total of 43 dogs entered; this was secondary to
a higher than anticipated number of dogs having meta-
static disease identified either prior to toceranib therapy
or immediately thereafter. Disease-free interval (DFI) and
survival time (ST) were calculated using the Kaplan-Meier
method for all dogs on an intent to treat basis and for only
those dogs that went on to receive toceranib following
completion of DOX therapy.
Results
Demographics
This was a multi-institutional study, with dogs enrolled
from multiple sites. A total of 43 dogs were enrolled from
April 2010 through June 2011. Baseline demographic infor-
mation for this patient population is presented in Table 1.
The median age of all dogs entered was 10 years and the
median weight was 29 kg. Golden retrievers (n = 13) were
the most commonly represented breed.
Outcome
Seven dogs (16 %) (n = 2 stage I; n = 5 stage II) failed
doxorubicin either before or at re-staging having obvious
metastatic disease in either the abdomen (n = 5) or chest
(n = 2). An additional 3 dogs (n = 2 stage I; n = 1 stage II)
were found to have metastatic disease shortly after tocer-
anib administration (brain n = 2, abdomen n = 1). In
these cases, metastasis was already suspected due to le-
sions identified on ultrasound. However, metastasis could
not be definitively confirmed until a bleeding event or
the presence of clinical signs at toceranib initiation were
subsequently found to be secondary to tumor spread (e.g.,
seizures, n = 2). Thus, 4 of 5 dogs with stage I HSA were
removed from the study either prior to or soon after start-
ing toceranib due to metastatic disease. One dog was
removed within 1 week of toceranib administration due to
owner non-compliance and another dog was removed
from the study within 1 week of toceranib therapy due to
a severe protein losing nephropathy. Therefore 31 dogs
went on to receive toceranib following completion of
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surgery and restaging prior to starting toceranib ranged
from 74–99 days (median 84 days).
The majority (n = 25) of dogs that received toceranib
developed metastatic disease. In most cases, this in-
volved the development of metastasis in the abdomen
(n = 16, liver, omentum, mesentery), lungs (n = 1), or
abdomen and lungs (n = 3). Other sites of metastasis in-
cluded the heart, bladder, brain, skin and kidney. Seven
dogs completed the study and were alive 1 year post
splenectomy (n = 1 stage I; n = 6 stage II). The medianFig. 1 Disease Free Interval: Kaplan-Meier disease-free interval (DFI) curves
observations. Dotted lines delineate the 95 % confidence interval. (a) Dogsdisease free interval for all dogs enrolled in this study (n =
43) was 138 days, and the median disease free interval for
those dogs that went on to receive toceranib (n = 31) was
161 days (Fig. 1). The median survival time for all dogs en-
rolled in this study was 169 days, and the median survival
time for those dogs that went on to receive toceranib was
172 days (Fig. 2). The 1 year survival rate was 21.2 % for
all dogs enrolled, and 24.4 % for dogs that received tocera-
nib. These data are consistent with prior publications
evaluating both chemotherapy and/or investigational
therapies in dogs with stage I or II HSA [6–8, 10–12].
Toceranib dosing
Dogs were initially assigned a dose of 3.25 mg/kg; how-
ever the actual dose of toceranib phosphate administered
was adjusted as needed for alterations in weight and AEs.
Fifteen dogs required a dose adjustment. The median dose
of toceranib administered over this study was 3 mg/kg
(range 1.7–3.25 mg/kg).
Adverse events
Adverse events are described for the 31 dogs that went
on to receive toceranib. AEs were similar to those previ-
ously reported for doxorubicin and toceranib. All drug-
related AEs were self-limiting and responsive to supportive
care. Gastrointestinal AEs consisting of vomiting, diarrhea
and anorexia were the primary drug-related toxicities
observed. Table 2 shows adverse events for all dogs that
received toceranib.
Hematologic
Low-grade anemia was prevalent throughout the study,
with 25 of 31 dogs (80 %) developing at least one episode
of grade 1 or 2 anemia. In all cases, grade 3 or 4 anemia
was secondary to progressive disease and occurred in
association with hemoabdomen. No dose adjustments or
temporary drug discontinuation were necessary for Grade
1 or 2 transient neutropenia.for dogs entered into the clinical trial. Hash marks denote censored
that received toceranib for longer than 1 week. (b) All dogs
Fig. 2 Overall Survival: Kaplain-Meier overall survival (OS) curves for dogs entered into the clinical trial. Hash marks denote censored observations.
Dotted lines delineate the 95 % confidence interval. (a) Dogs that received toceranib for longer than 1 week. (b) All dogs
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Low-grade elevations in BUN and hypoalbuminemia
were the most common biochemical toxicities. One dog
each developed a grade 3 and 4 elevation in BUN with-
out a concurrent increase in creatinine. No evidence of
hepatotoxicity was noted in dogs enrolled in this study.Table 2 Adverse events in toceranib treated dogs
Adverse event Grade
1 2 3 4 5
Vomiting 38 2 2
Diarrhea 32 9 2
Decreased HCT (Anemia) 26 13 2 2
Inappetance 20 6 3
Decreased hemoglobin 17 5 2 1
Weight Loss 11 1
Neutropenia 8 3
Increased CK 8
Lethargy 6 7 2
Elevated BUN 6 2 1 1
Alopecia 5 1




Trembling hind limbs 1
GI blood loss 1 2
Stiffness 3
Pancreatitis 2
Generalized weakness 1 3
Hemoabdomen 1 6 3Gastrointestinal
Grade 1 and 2 inappetance, vomiting and diarrhea resolved
with supportive care, temporary drug discontinuation, and/
or drug dose modifications. Grade 3 inappetance was asso-
ciated with progressive disease in all dogs (n = 3). Grade 1
and 2 weight loss was consistent with reported inappetance
in dogs.Neuromuscular
Grade 3 hind limb weakness was associated with pro-
gressive disease in all dogs. Grade 4 generalized weak-
ness, which was associated with progressive disease in 2
dogs and attributed to metronidazole toxicity in 1 dog.Other Adverse Events
Other side effects observed in dogs enrolled in this study
included: increased creatinine kinase, lameness, hind limb
trembling, stiffness, alopecia, pancreatitis and hemoabdo-
men. These adverse events could not be directly attributed
to toceranib therapy, and may have been secondary to
progression of disease or other unrelated causes.Discussion
Hemangiosarcoma (HSA) is a relatively common malig-
nancy that occurs in the canine population, yet little
progress in changing outcome has been achieved in the
past 20 years. While doxorubicin (DOX) based protocols
have improved survival times in dogs with resectable tu-
mors from an average of 3 months to 6 months, nearly
all dogs die due to metastatic disease within 1 year of
diagnosis, with most deaths occurring within 6–8 months
[2]. A variety of chemotherapy combinations have been
used, most of which are centered around the use of
doxorubicin (DOX) including DOX/cyclophosphamide,
DOX/cyclophosphamide/vincristine and liposomal DOX,
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tially better than the other [6, 8, 10, 11].
The current study was designed to evaluate the efficacy
of toceranib against stage I and II splenic HSA in the
microscopic disease setting following the administration
of DOX chemotherapy. The underlying premise in sup-
port of our hypothesis was that inhibition of both PDGFR
and VEGFR family members would have direct effects on
tumor cell growth as well as indirect effects on the tumor
microenvironment by virtue of presumed targeting of
tumor vasculature. Therapies targeting VEGFR in people
have largely resulted in modest benefits, and unfortu-
nately, in this clinical trial, toceranib did not provide a
measurable impact in dogs with splenic HSA with respect
to either DFI or OS when compared to previous clinical
investigations in this disease setting.
There have been several attempts to dissect the mo-
lecular mechanisms that drive HSA with the ultimate
goal of improving therapeutic outcome. Multiple recep-
tor tyrosine kinases are known to be expressed by HSA
tumor cells including KIT, PDGFR, and VEGFR, al-
though their contributions to tumor growth are not
clear [17, 18, 20–23, 32]. The small molecule inhibitors
imatinib, dasatinib, and masatinib have all shown activ-
ity against canine HSA cell lines in vitro, with evidence
of direct effects on PDGFR family members [16, 19].
Furthermore, imatinib demonstrated activity against
canine HSA mouse xenografts, supporting the role of
PDGFR signaling on tumor biology in vitro [16]. A
more recent immunohistochemical study found that
only 45 % of tumors were positive for PDGFRα and
63 % positive for PDGFRβ; however there was no evi-
dence of overexpression or activating receptor muta-
tions in the tumor samples evaluated [33]. These data
suggest that while PDGFRα/β expression may be de-
tected in HSA, the receptors likely do not play a critical
role in tumor growth, providing a possible explanation
for why toceranib was not beneficial in the study popu-
lation reported herein.
With respect to VEGF/VEGFR signaling, expression of
both ligand and receptor have been demonstrated in
tumor samples and cell lines providing some evidence
that this signaling pathway may be relevant in HSA biol-
ogy [18, 20, 22, 23]. While not yet demonstrated in the
clinical setting, several murine xenograft studies have
suggested that VEGFR inhibitors can promote a more
aggressive phenotype through the process of metastatic
conditioning [34–37]. This has raised concerns that the
use of VEGFR inhibitors in the setting of microscopic
disease could potentially accelerate the development me-
tastasis. Mechanisms proposed to drive tumor progression
and metastasis in the face of VEGFR inhibition include
vascular pruning leading to acute hypoxic stress, activa-
tion of alternative angiogenic pathways (e.g. signalingbetween the tumor stroma and cells of the immune
system) and up-regulation of proangiogenic factors
(e.g. FGF, PDGF), among others [38–42]. Interestingly,
one study found that VEGFR1 protein expression was
higher in tumors derived from Golden retrievers, and
that targeted inhibition of VEGFR1 increased prolifera-
tion of tumor cells derived from Golden Retrievers, but
not from other breeds [21]. These findings highlight
the notion that expression of a particular kinase does
not necessarily define its role as a driver in tumor biol-
ogy, and as such, inhibition of that kinase may have un-
expected consequences, such as acceleration of tumor
growth.
While VEGFR and PDGFR may contribute to tumor
cell growth in HSA, it is possible that cytoplasmic sig-
naling pathways downstream of these receptors are also
dysregulated thus limiting the effect of upstream inhib-
ition. For example, recently mitogen-activated protein/
extracellular signal-regulated kinase (MEK) inhibitors
reduced extracellular signal-regulated kinase (ERK) acti-
vation and the viability of primary cells derived from
visceral, cutaneous, and cardiac HSA in vitro, indicating
that this cytoplasmic kinase may be critical for sustained
tumor cell growth [24]. These cells were also sensitive
to sorafenib, an inhibitor of multiple receptor kinases
including VEGFR, PDGFR, KIT as well as the cytoplas-
mic kinase B-RAF. In vivo, both MEK inhibitors and
sorafenib decreased the growth of HSA xenografts in
mice. Similar results were observed with human angio-
sarcoma cell lines and xenografts, supporting a role for
the MEK signaling pathway in the biology of this disease
in both species.
There are other possible explanations for the failure of
toceranib to improve outcome in this clinical trial. Given
the conflicting data regarding the roles of PDGFR and
VEGFR family members based on immunohistochemical
staining, cell line studies, genomic analysis and murine
xenograft work, it is possible that these receptor tyrosine
kinases simply do not drive HSA tumor growth or sur-
vival. As such, inhibiting these pathways would provide
little benefit in dogs with disease. Alternatively, it may
be possible that these pathways play a role early on in
tumor cell growth and survival, but resistance to tocera-
nib develops early on and as such, an effect on disease
free interval is not observed. Lastly, there may be a limited
window of opportunity to affect the growth of microscopic
metastatic disease with toceranib and delaying treatment
until after DOX rather than concurrent with DOX may
have diminished any therapeutic effect. This may be par-
ticularly relevant for any anti-angiogenic effects as typical
cytotoxic chemotherapy based regimens have little impact
on angiogenesis mediated by circulating endothelial pre-
cursors thus potentially permitting microscopic disease to
develop a more mature vasculature that would be resistant
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toceranib on circulating endothelial precursor levels during
cytotoxic chemotherapy would be useful to determine if
concurrent treatment might be of benefit in dogs with
microscopic metastases.
In the present study, 7 dogs failed doxorubicin treat-
ment either before completion of DOX (n = 3) or at re-
staging (n = 4) and an additional 3 dogs were found to
have metastatic disease immediately following initiation
of toceranib therapy. With respect to dogs diagnosed
with stage I HSA, 4 of 5 were removed from the study
either prior to or soon after starting toceranib due to
disease progression. Given the small number of dogs
with stage I disease, statistically significant comparisons
cannot be made, however dogs with stage I disease did
not appear to have a survival benefit when compared to
those with stage II HSA. The fact that 23 % of dogs
developed disease recurrence within 3 months following
surgery and treatment with DOX underscores the ag-
gressive nature of this disease. Furthermore, the re-
ported median DFI and ST reported herein do not
represent an improvement upon previously published
reports of adjuvant chemotherapy for splenic HSA [6, 8–
10, 12]. It may therefore be of interest to determine
whether the inclusion of toceranib during DOX treatment
rather than following chemotherapy would provide a
greater survival benefit.
The adverse events associated with toceranib adminis-
tration were expected, consisting mainly of grade 1 and
2 gastrointestinal (GI) adverse events including inappe-
tance, weight loss, vomiting and diarrhea. The grade 3
and 4 GI adverse events were also similar to those in
previous studies [28–30]. In this study, 19 dogs had a
dose reduction in toceranib secondary to the develop-
ment of clinical toxicities and only 1 dog was removed
from the study due to toceranib effects that could not be
effectively managed with either a dose reduction or the
use of concomitant medications. More recently, doses of
toceranib between 2.5–2.75 mg were associated with
biologic activity of drug, clinical benefit to treated dogs,
and no grade 3 and 4 GI adverse events [43]. Therefore,
any future studies evaluating the concurrent administra-
tion of toceranib in combination with doxorubicin or
other chemotherapy agents could use this lower starting
dose of toceranib and potentially reduce the risk for
severe GI toxicities.
There are several weaknesses in this study that should
be noted. Due to the multi-institutional nature of the
study, there was likely inherent variability in data collec-
tion and interpretation and assessment of clinical toxic-
ities. To help ensure uniformity in the data, patient AEs
were assessed in accordance with VCOG-CTCAE cri-
teria and the primary investigator (C. London) provided
direction to all sites regarding management of AEs andrecommended dosing of toceranib throughout the study
period. In addition, this clinical trial lacked a prospective
control group that received doxorubicin alone and was
not randomized. Splenectomy and DOX-based chemo-
therapy is the standard treatment for splenic HSA in
dogs, and the addition of chemotherapy results in median
survival times of approximately 6–8 months [2]. Our re-
sults were compared to historical information published
on dogs undergoing chemotherapy and splenectomy. Al-
though there were many similarities between our patient
population and the historical populations, it is difficult to
make direct comparisons. Lastly, the presence of meta-
static disease at staging was ambiguous in some cases, and
may have resulted in enrollment of dogs with uncon-
firmed early metastatic disease. This was most evident in
the stage I dogs, in which 4 of 5 dogs were removed from
the study early on due to metastatic disease.
As previously discussed, it is possible that toceranib
may provide a greater benefit when administered earlier
in the treatment protocol. To address this, toceranib
could potentially be given concurrently with the DOX.
This may be advantageous as DOX has been shown to
inhibit HIF1-α [44], thus offsetting the hypoxic effects of
vascular pruning induced by VEGFR inhibition. MTD
chemotherapy has been combined with toceranib in the
treatment of some solid tumors [45, 46]. These studies
showed that toceranib often sensitizes the myeloid com-
partment to the effects of cytotoxic chemotherapy result-
ing in severe neutropenia, necessitating dose reductions in
the chemotherapy. If DOX were to be used concurrently
with toceranib in dogs with HSA, it is probable that lower
doses would be required to avoid severe adverse events,
thus potentially mitigating the benefit of cytotoxic
chemotherapy. Nevertheless, antitumor responses are
still observed in this setting of combined chemother-
apy/toceranib in which the chemotherapy dose has been
reduced to below that typically used in treatment. For
example, in dogs receiving combined vinblastine/Palla-
dia for the treatment of mast cell tumors, the chemo-
therapy dose was decreased to 1.6 mg/m2 (standard
dose is 2–2.5 mg/m2), yet the objective response rate in
treated patients was 70 % [46].
Conclusions
In summary, the data reported in this manuscript demon-
strate that the use of toceranib following DOX chemother-
apy does not improve either DFI or OS in dogs with stage
I and II HSA. Given the early failure rate in a high per-
centage of dogs enrolled in this study, future studies with
DOX and toceranib in addition to metronomic therapy
with low-dose cyclophosphamide may be warranted to de-
termine if concurrent rather than sequential administra-
tion of these therapies has a significant impact on disease
progression in dogs with HSA.
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